Member Info for bigsmoke

Soz - even better............. "Metals One holds 4,250,000 shares in Fulcrum, representing approximately 2.99% of Fulcrum's issued share capital, in addition to 1,458,334 warrants with an exercise price of 10 pence expiring in July 2027."

Is it still 2.88% shareholding there?

Soil sampling results of up to 1.46g/t gold advance high-grade drill

Fulcrum Metals plc (AIM:FMET), a company pioneering the use of innovative cyanide free technology to recover precious and critical metals from mine waste with additional interests in highly prospective exploration projects, is pleased to announce soil sampling results of up to 1.46g/t gold at its Big Bear Exploration Project ("Big Bear" or the "Project") in Ontario, Canada. The results define a large-scale gold target within a wider gold corridor and further advance multiple permitted, drill-ready targets ahead of future exploration activities.

Highlights

· Regional stand-out ~2km × 2km gold target defined within 3km gold corridor

· 1460 ppb (1.46g/t) Au peak soil results; 51 highly anomalous samples over 30ppb Au

· 3km gold corridor with rock samples of up to 139g/t Au

· Strong correlation between high-grade soil and rock samples enhances drill targeting and extends bedrock targets

· Gold target and corridor remains open for expansion

· 30 drill pads permitted; multiple priority targets ready for drilling

Ryan Mee, Chief Executive Officer of Fulcrum, commented: "The soil sampling programme has defined a regional stand-out gold target within a 3km corridor that remains open along strike. Results are supported by a growing dataset of high-grade soil samples grading up to 1.82 g/t Au and rock samples up to 139 g/t Au, highlighting the scale and prospectivity of the system.

Soil sampling continues to be an effective tool for targeting mineralisation in areas of limited bedrock exposure, enhancing drill targeting and supporting expansion of the known gold footprint. With permits in place for up to 30 drill pads, Big Bear is a high-grade, drill-ready gold project with multiple priority targets.

Our focus is now on evaluating partnership opportunities for Big Bear, consistent with our strategy at the Tully Gold Project and across our uranium portfolio."

Tastey

Fulcrum Metals plc (AIM:FMET), a company pioneering the use of innovative cyanide free technology to recover precious and critical metals from mine waste with additional interests in highly prospective exploration projects, is pleased to announce soil sampling results of up to 1.46g/t gold at its Big Bear Exploration Project ("Big Bear" or the "Project") in Ontario, Canada. The results define a large-scale gold target within a wider gold corridor and further advance multiple permitted, drill-ready targets ahead of future exploration activities.

Highlights

· Regional stand-out ~2km × 2km gold target defined within 3km gold corridor

· 1460 ppb (1.46g/t) Au peak soil results; 51 highly anomalous samples over 30ppb Au

· 3km gold corridor with rock samples of up to 139g/t Au

· Strong correlation between high-grade soil and rock samples enhances drill targeting and extends bedrock targets

· Gold target and corridor remains open for expansion

· 30 drill pads permitted; multiple priority targets ready for drilling

Ryan Mee, Chief Executive Officer of Fulcrum, commented: "The soil sampling programme has defined a regional stand-out gold target within a 3km corridor that remains open along strike. Results are supported by a growing dataset of high-grade soil samples grading up to 1.82 g/t Au and rock samples up to 139 g/t Au, highlighting the scale and prospectivity of the system.

Soil sampling continues to be an effective tool for targeting mineralisation in areas of limited bedrock exposure, enhancing drill targeting and supporting expansion of the known gold footprint. With permits in place for up to 30 drill pads, Big Bear is a high-grade, drill-ready gold project with multiple priority targets.

Our focus is now on evaluating partnership opportunities for Big Bear, consistent with our strategy at the Tully Gold Project and across our uranium portfolio."

.. eh .. what about the 10% on the loan?

lots of deliberate overlooking going on here...

Castlelake would be required to make an offer at no less than 403.23 pence per share.

Record Monthly Dispensing Volume - Best Month Since Launch

Over 250,000 Prescription Items Dispensed Since Launch

MedPal AI plc (AIM: MPAL; FRA: Z1N), the AI-powered, integrated digital health and pharmacy company, is pleased to provide an operational update on the continued strong growth in dispensing volumes at its wholly owned pharmacy operations.

• Record month: over 42,250 prescription items dispensed in May 2026 - the Company's best-performing month since pharmacy operations commenced, surpassing the previous record of 41,000 items, reflecting underlying momentum in patient demand.

• Major cumulative milestone: the Company has now dispensed over 250,000 prescription items in total since launch, underscoring the sustained, accelerating adoption of its NHS and private pharmacy services and the Company's dispensing platform retains substantial headroom for further growth.

• Strong margins: as reported in the Company's interim results for the six months ended 28 February 2026, pharmacy gross margin strengthened to over 34% as dispensing volumes scaled, reflecting the operational leverage of the Company's automated dispensing model.

• Annualised run rate: based on the May 2026 dispensing volume the Company's pharmacy operations are now trading at an annualised turnover run rate in excess of £5 million.

Chief Executive Officer's commentary

Jason Drummond, Founder and Chief Executive Officer of MedPal AI, commented:

"May was our best month yet, with over 42,250 items dispensed, and we have now passed a quarter of a million prescriptions since we began. To reach this scale in such a short period is a powerful validation of our automated, technology-led model - which, as our interim results showed, is delivering pharmacy gross margins of over 34% as we grow. We have built this momentum from a standing start, and with significant capacity still available across our dispensing operations, the Board sees a clear runway for continued, profitable growth."

Caledonian Holdings PLC

("Caledonian" or the "Company")

Completion of acquisition of Aspire Commerce Group Limited

Transformational acquisition accelerates execution of Caledonian's strategy to build an integrated financial services group

Caledonian Holdings PLC (AIM: CHP), the AIM quoted investing company focused on building an integrated financial services group, is pleased to announce the completion of the acquisition of the entire issued share capital of Aspire Commerce Group Limited ("Aspire") (the "Acquisition").

Under the terms of the Acquisition, Caledonian has acquired Aspire for a nominal cash consideration implying an enterprise value of £9.33 million on completion.

The Acquisition has completed following receipt of Financial Conduct Authority ("FCA") change in control approval and shareholder approval at the Company's recent annual general meeting.

Aspire is a payments, foreign exchange and trade finance business operating through Aspire Lending Limited and Aspire Payments Limited. Aspire Payments Limited is authorised and regulated by the FCA as a Small Electronic Money Institution.

Strategic highlights

· Step change in scale and capability. The Acquisition materially strengthens Caledonian's financial services offering and operational infrastructure and marks a step change in the scale and ambition of the business.

· Significant new funding capacity. The transaction provides Aspire with access to an initial additional funding line of up to £30 million, providing substantial new capacity to accelerate growth initiatives.

· Multiple funding channels. The Acquisition is expected to broaden access to further funding lines, enhancing Caledonian's ability to deploy capital in high-value opportunities.

· Rapidly expanding pipeline. Aspire has an active customer pipeline of approximately £12.5 million, together with strong momentum expected to drive a material uplift in near-term activity.

· Value-enhancing strategic fit. The Board believes the combination of Caledonian's public market platform and financial services strategy with Aspire's proprietary technology, regulated infrastructure and operational capabilities creates a compelling platform for future growth, with the potential to deliver shareholder value through increased scale, capability expansion and operational leverage.

The Acquisition provides Caledonian with:

· a regulated payments business;

· established customer and transaction infrastructure;

· capabilities across payments, foreign exchange and trade finance; and

· proprietary technology supporting customer payments, foreign exchange transactions and working capital solutions.

Operational highlights

Aspire's electronic payment account and foreign exchange services commenced commercial operations in May 2024, with trade finance operations launching in May 2025.

To date, Aspire's growth has been achieved with limited external marketing activity and under significa

Grant Award

Award of Non-Dilutive Grant to Advance Docetaxel-ChemoSeed Programme in Prostate Cancer

CRISM Therapeutics Corporation (AIM: CRTX), a UK clinical-stage drug delivery company focused on the localised and sustained delivery of chemotherapy drugs, is pleased to announce that it has been awarded a non-dilutive research and development grant of up to £99,902 from Invest Northern Ireland ("InvestNI") representing 61% of eligible project expenditure, to support the continued development of its docetaxel-ChemoSeed programme for the treatment of prostate cancer.

The grant provides targeted funding to accelerate key technical, preclinical and regulatory activities through non-dilutive capital. The funded programme of work is scheduled to run through to March 2027.

The Board believes this award reflects the commercial potential of the ChemoSeed platform and its application in prostate cancer, one of the largest oncology markets globally. This funding enables CRISM to advance critical development milestones, while maintaining capital efficiency and strengthening the overall value proposition of the programme.

The grant will support a focused programme of work designed to progress docetaxel-ChemoSeed toward clinical development, including:

1. Development and optimisation of a scalable manufacturing process

2. Establishment and validation of analytical methods

3. Scale-up of manufacturing processes to support future Good Manufacturing Practice (GMP) translation

4. In vivo pharmacokinetic, efficacy, and toxicity studies to further define the therapeutic profile of the programme

5. Preparation for regulatory engagement, including planning for scientific advice with the Medicines and Healthcare products Regulatory Agency ("MHRA") and mapping clinical trial requirements

Docetaxel-ChemoSeed is designed to deliver localised, sustained chemotherapy directly to tumour tissue, with the aim of improving therapeutic outcomes while reducing systemic toxicity associated with conventional administration.

Prostate cancer remains one of the most prevalent cancers worldwide, with a significant clinical and economic burden. The Board believes that targeted local delivery approaches such as ChemoSeed have the potential to address key limitations of current treatment paradigms.

The funded programme is expected to generate critical data and the manufacturing capability required to support future regulatory submissions and clinical development, positioning the asset for potential partnering, licensing, or further non-dilutive funding opportunities.

Professor Chris McConville, Chief Scientific Officer of CRISM Therapeutics, commented:"We are delighted to secure this Invest NI grant, as it enables us to accelerate the development of our docetaxel-ChemoSeed prostate cancer programme. Non-dilutive funding of this kind is invaluable as it permits us to advance manufacturing, preclinical and regulato

Block Listing Returns

Total Voting Rights

Transaction in Own Shares

The ret is waffle IMO.

Admin expenses UP; production DOWN.

company not going right way.

Not quite a boom

Are we waiting for the placing shares to clear?

Hopefully! been a few false dawns though

Why Pete? Is this yet another another baseless statement?

Hmm